AMPHASTAR PHARMACEUTICALS IN (AMPH)
US03209R1032 - Common Stock
Taking everything into account, AMPH scores 6 out of 10 in our fundamental rating. AMPH was compared to 198 industry peers in the Pharmaceuticals industry. While AMPH has a great profitability rating, there are some minor concerns on its financial health. AMPH scores decently on growth, while it is valued quite cheap. This could make an interesting combination. This makes AMPH very considerable for value investing!
1. Profitability
1.1 Basic Checks
In the past year AMPH was profitable.
In the past year AMPH had a positive cash flow from operations.
Each year in the past 5 years AMPH has been profitable.
In the past 5 years AMPH always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of AMPH (9.09%) is better than 93.33% of its industry peers.
The Return On Equity of AMPH (21.50%) is better than 92.82% of its industry peers.
With an excellent Return On Invested Capital value of 12.33%, AMPH belongs to the best of the industry, outperforming 91.28% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for AMPH is below the industry average of 16.40%.
The 3 year average ROIC (11.94%) for AMPH is below the current ROIC(12.33%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.09% | ||
| ROE | 21.5% | ||
| ROIC | 12.33% |
ROA(3y)10.22%
ROA(5y)7.84%
ROE(3y)17.58%
ROE(5y)13.18%
ROIC(3y)11.94%
ROIC(5y)N/A
1.3 Margins
AMPH has a Profit Margin of 21.33%. This is amongst the best in the industry. AMPH outperforms 93.33% of its industry peers.
In the last couple of years the Profit Margin of AMPH has grown nicely.
With an excellent Operating Margin value of 30.57%, AMPH belongs to the best of the industry, outperforming 94.87% of the companies in the same industry.
AMPH's Operating Margin has improved in the last couple of years.
AMPH has a Gross Margin of 54.48%. This is in the better half of the industry: AMPH outperforms 63.08% of its industry peers.
In the last couple of years the Gross Margin of AMPH has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.57% | ||
| PM (TTM) | 21.33% | ||
| GM | 54.48% |
OM growth 3Y114.39%
OM growth 5YN/A
PM growth 3Y276.41%
PM growth 5YN/A
GM growth 3Y10.26%
GM growth 5Y8.62%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AMPH is still creating some value.
Compared to 1 year ago, AMPH has about the same amount of shares outstanding.
Compared to 5 years ago, AMPH has more shares outstanding
AMPH has a worse debt/assets ratio than last year.
2.2 Solvency
AMPH has an Altman-Z score of 2.83. This is not the best score and indicates that AMPH is in the grey zone with still only limited risk for bankruptcy at the moment.
AMPH's Altman-Z score of 2.83 is fine compared to the rest of the industry. AMPH outperforms 73.85% of its industry peers.
The Debt to FCF ratio of AMPH is 4.06, which is a neutral value as it means it would take AMPH, 4.06 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.06, AMPH belongs to the top of the industry, outperforming 87.69% of the companies in the same industry.
AMPH has a Debt/Equity ratio of 0.92. This is a neutral value indicating AMPH is somewhat dependend on debt financing.
The Debt to Equity ratio of AMPH (0.92) is worse than 73.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.92 | ||
| Debt/FCF | 4.06 | ||
| Altman-Z | 2.83 |
ROIC/WACC1.43
WACC8.63%
2.3 Liquidity
AMPH has a Current Ratio of 2.17. This indicates that AMPH is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of AMPH (2.17) is worse than 64.62% of its industry peers.
AMPH has a Quick Ratio of 1.70. This is a normal value and indicates that AMPH is financially healthy and should not expect problems in meeting its short term obligations.
AMPH has a Quick ratio of 1.70. This is in the lower half of the industry: AMPH underperforms 65.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.17 | ||
| Quick Ratio | 1.7 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 67.51% over the past year.
Measured over the past years, AMPH shows a very strong growth in Earnings Per Share. The EPS has been growing by 70.36% on average per year.
The Revenue has grown by 29.14% in the past year. This is a very strong growth!
Measured over the past years, AMPH shows a quite strong growth in Revenue. The Revenue has been growing by 16.94% on average per year.
EPS 1Y (TTM)67.51%
EPS 3Y72.76%
EPS 5Y70.36%
EPS growth Q2Q20.55%
Revenue 1Y (TTM)29.14%
Revenue growth 3Y22.59%
Revenue growth 5Y16.94%
Revenue growth Q2Q31.93%
3.2 Future
Based on estimates for the next years, AMPH will show a decrease in Earnings Per Share. The EPS will decrease by -4.87% on average per year.
AMPH is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.16% yearly.
EPS Next Y16.12%
EPS Next 2Y15.67%
EPS Next 3Y15.63%
EPS Next 5Y-4.87%
Revenue Next Year15.21%
Revenue Next 2Y12.56%
Revenue Next 3Y11.29%
Revenue Next 5Y1.16%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 12.75, the valuation of AMPH can be described as correct.
AMPH's Price/Earnings ratio is rather cheap when compared to the industry. AMPH is cheaper than 90.26% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 24.55, AMPH is valued a bit cheaper.
AMPH is valuated reasonably with a Price/Forward Earnings ratio of 10.98.
Based on the Price/Forward Earnings ratio, AMPH is valued cheaper than 91.28% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 20.92, AMPH is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.75 | ||
| Fwd PE | 10.98 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AMPH is valued cheaper than 86.67% of the companies in the same industry.
89.23% of the companies in the same industry are more expensive than AMPH, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.15 | ||
| EV/EBITDA | 9.52 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AMPH has an outstanding profitability rating, which may justify a higher PE ratio.
AMPH's earnings are expected to grow with 15.63% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.79
PEG (5Y)0.18
EPS Next 2Y15.67%
EPS Next 3Y15.63%
5. Dividend
5.1 Amount
No dividends for AMPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AMPHASTAR PHARMACEUTICALS IN
NASDAQ:AMPH (5/1/2024, 3:20:00 PM)
After market: 42.08 0 (0%)42.08
+0.83 (+2.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.06B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.75 | ||
| Fwd PE | 10.98 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.79
PEG (5Y)0.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.09% | ||
| ROE | 21.5% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 30.57% | ||
| PM (TTM) | 21.33% | ||
| GM | 54.48% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.92 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.17 | ||
| Quick Ratio | 1.7 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)67.51%
EPS 3Y72.76%
EPS 5Y
EPS growth Q2Q
EPS Next Y16.12%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)29.14%
Revenue growth 3Y22.59%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y